Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.86 Billion USD | 10.17% |
| 2022 | 8.93 Billion USD | 17.91% |
| 2021 | 7.57 Billion USD | 22.06% |
| 2020 | 6.2 Billion USD | 49.07% |
| 2019 | 4.16 Billion USD | 36.59% |
| 2018 | 3.04 Billion USD | 22.46% |
| 2017 | 2.48 Billion USD | 46.2% |
| 2016 | 1.7 Billion USD | 64.89% |
| 2015 | 1.03 Billion USD | 77.86% |
| 2014 | 580.41 Million USD | -52.11% |
| 2013 | 1.21 Billion USD | -20.63% |
| 2012 | 1.52 Billion USD | 8.25% |
| 2011 | 1.41 Billion USD | 883.91% |
| 2010 | 143.37 Million USD | 40.49% |
| 2009 | 102.04 Million USD | -41.85% |
| 2008 | 175.5 Million USD | -11.81% |
| 2007 | 199.01 Million USD | -8.02% |
| 2006 | 216.35 Million USD | 34.47% |
| 2005 | 160.89 Million USD | 56.63% |
| 2004 | 102.71 Million USD | 48.56% |
| 2003 | 69.14 Million USD | -57.08% |
| 2002 | 161.08 Million USD | -3.82% |
| 2001 | 167.49 Million USD | 114.38% |
| 2000 | 78.12 Million USD | 26.83% |
| 1999 | 61.6 Million USD | 38.74% |
| 1998 | 44.4 Million USD | 1.37% |
| 1997 | 43.8 Million USD | 229.32% |
| 1996 | 13.3 Million USD | -39.82% |
| 1995 | 22.1 Million USD | 12.76% |
| 1994 | 19.6 Million USD | -29.75% |
| 1993 | 27.9 Million USD | 634.21% |
| 1992 | 3.8 Million USD | 18.75% |
| 1991 | 3.2 Million USD | 39.13% |
| 1990 | 2.3 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 2.77 Billion USD | 5.21% |
| 2024 Q2 | 2.63 Billion USD | -1.95% |
| 2024 Q1 | 2.68 Billion USD | 6.73% |
| 2023 Q1 | 2.37 Billion USD | 3.13% |
| 2023 Q4 | 2.51 Billion USD | 1.38% |
| 2023 FY | 9.83 Billion USD | 10.17% |
| 2023 Q2 | 2.49 Billion USD | 4.99% |
| 2023 Q3 | 2.48 Billion USD | -0.39% |
| 2022 Q4 | 2.3 Billion USD | -1.35% |
| 2022 Q1 | 2.09 Billion USD | 1.2% |
| 2022 Q2 | 2.19 Billion USD | 4.71% |
| 2022 FY | 8.93 Billion USD | 17.91% |
| 2022 Q3 | 2.33 Billion USD | 6.29% |
| 2021 Q1 | 1.72 Billion USD | 5.93% |
| 2021 Q2 | 1.79 Billion USD | 4.01% |
| 2021 Q4 | 2.07 Billion USD | 4.46% |
| 2021 FY | 7.57 Billion USD | 22.06% |
| 2021 Q3 | 1.98 Billion USD | 10.64% |
| 2020 Q1 | 1.51 Billion USD | 7.21% |
| 2020 FY | 6.2 Billion USD | 49.07% |
| 2020 Q4 | 1.62 Billion USD | 5.82% |
| 2020 Q3 | 1.53 Billion USD | 0.9% |
| 2020 Q2 | 1.52 Billion USD | 0.62% |
| 2019 FY | 4.16 Billion USD | 36.59% |
| 2019 Q1 | 858.43 Million USD | -1.34% |
| 2019 Q4 | 1.41 Billion USD | 48.79% |
| 2019 Q3 | 949.82 Million USD | 0.91% |
| 2019 Q2 | 941.29 Million USD | 9.65% |
| 2018 Q2 | 752.15 Million USD | 17.38% |
| 2018 Q4 | 870.1 Million USD | 10.91% |
| 2018 FY | 3.04 Billion USD | 22.46% |
| 2018 Q1 | 640.79 Million USD | -1.66% |
| 2018 Q3 | 784.53 Million USD | 4.3% |
| 2017 Q3 | 578.16 Million USD | 6.25% |
| 2017 Q2 | 544.13 Million USD | -23.87% |
| 2017 Q1 | 714.71 Million USD | 55.81% |
| 2017 Q4 | 651.63 Million USD | 12.71% |
| 2017 FY | 2.48 Billion USD | 46.2% |
| 2016 Q2 | 431.6 Million USD | 8.42% |
| 2016 FY | 1.7 Billion USD | 64.89% |
| 2016 Q1 | 398.08 Million USD | -4.75% |
| 2016 Q3 | 413.78 Million USD | -4.13% |
| 2016 Q4 | 458.7 Million USD | 10.86% |
| 2015 Q4 | 417.93 Million USD | 34.9% |
| 2015 Q1 | 138.5 Million USD | -4.18% |
| 2015 Q2 | 166.07 Million USD | 19.9% |
| 2015 FY | 1.03 Billion USD | 77.86% |
| 2015 Q3 | 309.81 Million USD | 86.55% |
| 2014 Q3 | 178.98 Million USD | 29.31% |
| 2014 Q2 | 138.42 Million USD | 16.86% |
| 2014 Q4 | 144.55 Million USD | -19.24% |
| 2014 FY | 580.41 Million USD | -52.11% |
| 2014 Q1 | 118.45 Million USD | -66.27% |
| 2013 Q3 | 221.7 Million USD | -28.66% |
| 2013 Q2 | 310.75 Million USD | -5.37% |
| 2013 Q1 | 328.36 Million USD | -1.68% |
| 2013 Q4 | 351.15 Million USD | 58.39% |
| 2013 FY | 1.21 Billion USD | -20.63% |
| 2012 Q4 | 333.99 Million USD | -0.6% |
| 2012 Q3 | 336 Million USD | -19.67% |
| 2012 Q2 | 418.3 Million USD | -4.66% |
| 2012 Q1 | 438.73 Million USD | -22.12% |
| 2012 FY | 1.52 Billion USD | 8.25% |
| 2011 FY | 1.41 Billion USD | 883.91% |
| 2011 Q1 | 73.66 Million USD | 12.42% |
| 2011 Q2 | 114.42 Million USD | 55.34% |
| 2011 Q3 | 659.2 Million USD | 476.1% |
| 2011 Q4 | 563.34 Million USD | -14.54% |
| 2010 Q4 | 65.52 Million USD | 175.37% |
| 2010 FY | 143.37 Million USD | 40.49% |
| 2010 Q1 | 22.42 Million USD | -33.82% |
| 2010 Q2 | 31.62 Million USD | 40.99% |
| 2010 Q3 | 23.79 Million USD | -24.75% |
| 2009 Q1 | 23.97 Million USD | -26.92% |
| 2009 Q4 | 33.88 Million USD | 35.79% |
| 2009 FY | 102.04 Million USD | -41.85% |
| 2009 Q2 | 19.06 Million USD | -20.5% |
| 2009 Q3 | 24.95 Million USD | 30.91% |
| 2008 FY | 175.5 Million USD | -11.81% |
| 2008 Q1 | 41.67 Million USD | -18.27% |
| 2008 Q3 | 31.6 Million USD | -54.46% |
| 2008 Q2 | 69.4 Million USD | 66.55% |
| 2008 Q4 | 32.81 Million USD | 3.8% |
| 2007 Q2 | 38.19 Million USD | -44.49% |
| 2007 Q1 | 68.81 Million USD | -27.0% |
| 2007 FY | 199.01 Million USD | -8.02% |
| 2007 Q3 | 41.01 Million USD | 7.38% |
| 2007 Q4 | 50.99 Million USD | 24.33% |
| 2006 FY | 216.35 Million USD | 34.47% |
| 2006 Q4 | 94.25 Million USD | 76.87% |
| 2006 Q3 | 53.28 Million USD | 79.27% |
| 2006 Q2 | 29.72 Million USD | -23.95% |
| 2006 Q1 | 39.08 Million USD | -38.69% |
| 2005 Q4 | 63.75 Million USD | 76.09% |
| 2005 Q2 | 32.32 Million USD | 12.99% |
| 2005 Q3 | 36.2 Million USD | 12.02% |
| 2005 FY | 160.89 Million USD | 56.63% |
| 2005 Q1 | 28.6 Million USD | -28.19% |
| 2004 Q3 | 26.82 Million USD | 44.7% |
| 2004 Q2 | 18.54 Million USD | 5.87% |
| 2004 Q1 | 17.51 Million USD | 65.15% |
| 2004 FY | 102.71 Million USD | 48.56% |
| 2004 Q4 | 39.83 Million USD | 48.48% |
| 2003 Q2 | 17.57 Million USD | -22.26% |
| 2003 Q4 | 10.6 Million USD | -42.22% |
| 2003 Q3 | 18.35 Million USD | 4.42% |
| 2003 Q1 | 22.6 Million USD | -48.36% |
| 2003 FY | 69.14 Million USD | -57.08% |
| 2002 Q1 | 40.69 Million USD | -21.02% |
| 2002 FY | 161.08 Million USD | -3.82% |
| 2002 Q3 | 34.27 Million USD | -19.03% |
| 2002 Q4 | 43.78 Million USD | 27.74% |
| 2002 Q2 | 42.33 Million USD | 4.02% |
| 2001 Q2 | 21.44 Million USD | 12.52% |
| 2001 Q3 | 40.36 Million USD | 88.26% |
| 2001 Q1 | 19.05 Million USD | -3.28% |
| 2001 Q4 | 51.52 Million USD | 27.64% |
| 2001 FY | 167.49 Million USD | 114.38% |
| 2000 Q2 | 37.03 Million USD | 392.28% |
| 2000 FY | 78.12 Million USD | 26.83% |
| 2000 Q4 | 19.7 Million USD | 42.1% |
| 2000 Q3 | 13.86 Million USD | -62.56% |
| 2000 Q1 | 7.52 Million USD | -74.58% |
| 1999 Q2 | 15.3 Million USD | 282.5% |
| 1999 Q1 | 4 Million USD | -65.81% |
| 1999 FY | 61.6 Million USD | 38.74% |
| 1999 Q3 | 9.6 Million USD | -37.25% |
| 1999 Q4 | 29.6 Million USD | 208.33% |
| 1998 Q4 | 11.7 Million USD | -36.41% |
| 1998 FY | 44.4 Million USD | 1.37% |
| 1998 Q1 | 3.2 Million USD | -71.43% |
| 1998 Q2 | 7.2 Million USD | 125.0% |
| 1998 Q3 | 18.4 Million USD | 155.56% |
| 1997 Q1 | 6.9 Million USD | 43.75% |
| 1997 Q2 | 12.2 Million USD | 76.81% |
| 1997 Q4 | 11.2 Million USD | -17.04% |
| 1997 Q3 | 13.5 Million USD | 10.66% |
| 1997 FY | 43.8 Million USD | 229.32% |
| 1996 Q2 | 3.1 Million USD | 24.0% |
| 1996 Q4 | 4.8 Million USD | 65.52% |
| 1996 FY | 13.3 Million USD | -39.82% |
| 1996 Q3 | 2.9 Million USD | -6.45% |
| 1996 Q1 | 2.5 Million USD | -69.51% |
| 1995 Q1 | 5.1 Million USD | 88.89% |
| 1995 FY | 22.1 Million USD | 12.76% |
| 1995 Q3 | 2.3 Million USD | -64.62% |
| 1995 Q4 | 8.2 Million USD | 256.52% |
| 1995 Q2 | 6.5 Million USD | 27.45% |
| 1994 FY | 19.6 Million USD | -29.75% |
| 1994 Q1 | 5.6 Million USD | -68.89% |
| 1994 Q2 | 4.8 Million USD | -14.29% |
| 1994 Q4 | 2.7 Million USD | -58.46% |
| 1994 Q3 | 6.5 Million USD | 35.42% |
| 1993 FY | 27.9 Million USD | 634.21% |
| 1993 Q1 | 900 Thousand USD | -10.0% |
| 1993 Q2 | 4.6 Million USD | 411.11% |
| 1993 Q4 | 18 Million USD | 309.09% |
| 1993 Q3 | 4.4 Million USD | -4.35% |
| 1992 Q2 | 1 Million USD | 11.11% |
| 1992 Q1 | 900 Thousand USD | 12.5% |
| 1992 FY | 3.8 Million USD | 18.75% |
| 1992 Q3 | 1 Million USD | 0.0% |
| 1992 Q4 | 1 Million USD | 0.0% |
| 1991 Q1 | 800 Thousand USD | 33.33% |
| 1991 Q4 | 800 Thousand USD | 0.0% |
| 1991 FY | 3.2 Million USD | 39.13% |
| 1991 Q3 | 800 Thousand USD | 0.0% |
| 1991 Q2 | 800 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| 1990 Q4 | 600 Thousand USD | 0.0% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 FY | 2.3 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -12532.899% |
| Dynavax Technologies Corporation | 232.28 Million USD | -4148.764% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -1524.504% |
| Perrigo Company plc | 4.65 Billion USD | -111.986% |
| Illumina, Inc. | 4.5 Billion USD | -119.121% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 76.972% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -829942.052% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 93.316% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 34.135% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -7668.332% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 24.761% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | -233.823% |
| Biogen Inc. | 9.83 Billion USD | -0.342% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -5500.118% |
| Evolus, Inc. | 202.08 Million USD | -4783.688% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -46967.913% |
| bluebird bio, Inc. | 29.49 Million USD | -33358.318% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -8383.504% |
| FibroGen, Inc. | 147.75 Million USD | -6579.571% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -44.434% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 148486.709% |
| Geron Corporation | 237 Thousand USD | -4164119.409% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -439.804% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -2371.279% |
| Myriad Genetics, Inc. | 678.4 Million USD | -1354.776% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -27106.616% |
| Zoetis Inc. | 8.54 Billion USD | -15.51% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -281877.143% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -160.517% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -307.949% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -1152.998% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -115019.561% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -10850.933% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -3547.154% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -31482.451% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -693.768% |
| OPKO Health, Inc. | 863.49 Million USD | -1042.937% |
| Exelixis, Inc. | 1.83 Billion USD | -439.239% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -422.982% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -1945.96% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -62193.757% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -3857.495% |
| Insmed Incorporated | 305.2 Million USD | -3133.598% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -1090.131% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -36693.796% |
| TG Therapeutics, Inc. | 233.66 Million USD | -4123.708% |
| Incyte Corporation | 3.69 Billion USD | -167.049% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -840.551% |